SARS-CoV-2 (Covid19)
8
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
14 treatments under study, led by Evusheld
Research Leaders
20 sponsors active, led by AstraZeneca
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (8)
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
eVusheld Assessment reaL wORld Effectiveness at UPMC
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers
First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
Rapid Screening Circuit of COVID 19 in Schools, Pilot Study
Research Network
Common Treatments
- Evusheld2
- Poc Sarscov2 Igg Antibody Test1
- Covigen C19 08 Mg Id Or Placebo Id1
- Sarscov2 Omicron Eg51 Challenge Agent 106 Tcid501
- Sarscov2 Omicron Eg51 Challenge Agent 104 Tcid501
Active Sponsors
- AstraZeneca2
- Telethon Kids Institute1
- Imperial College London1
- Bionet Co., Ltd1
- Imperial College Healthcare NHS Trust1
Top Investigators
Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
National Institute of Infectious Diseases, Bucharest, Romania
VA Informatics and Computing Infrastructure (VINCI)
Imperial College London
University of Sydney